Search results
3 Reasons to Buy AbbVie Stock on the Dip
Motley Fool via Yahoo Finance· 11 hours agoIt's been more than a year since AbbVie (NYSE: ABBV) lost patent exclusivity for its most important product, Humira, an immunology medicine. Though this...
Decoding AbbVie Inc (ABBV): A Strategic SWOT Insight
GuruFocus.com via Yahoo Finance· 2 days agoAbbVie's acquisition of ImmunoGen strengthens its oncology pipeline and solid tumor capabilities. Robust financial performance with $12.3 billion in net...
AbbVie Inc. (NYSE:ABBV) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 6 days agoAbbVie Inc. (NYSE:ABBV) Q1 2024 Earnings Call Transcript April 26, 2024 AbbVie Inc. beats earnings...
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
Zacks via Yahoo Finance· 5 days agoAbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you...
Michael Burgess trades in AbbVie, IBM, iShares ETF, and Merck stocks By Investing.com
Investing.com· 2 days agoMichael Burgess trades in AbbVie, IBM, iShares ETF, and Merck stocks
Investors Take AbbVie To The Woodshed. But Its Woes Are 'Unfounded.'Investors Take AbbVie To The...
Investor's Business Daily· 7 days agoOn Friday, AbbVie beat first-quarter expectations, largely on the back of its immunology franchise....
Earnings Beat: AbbVie Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Simply Wall St. via Yahoo Finance· 6 days agoAbbVie Inc. (NYSE:ABBV) investors will be delighted, with the company turning in some strong numbers...
Healthy Returns: Sales of Humira are plunging, but AbbVie has two promising successors
CNBC· 5 days agoSales of AbbVie's Humira are plummeting as the once-top-selling drug fights competition from cheaper...
AbbVie (NYSE:ABBV) Price Target Cut to $187.00
ETF DAILY NEWS· 5 days agoAbbVie (NYSE:ABBV – Get Free Report) had its target price cut by equities researchers at Barclays from $195.00 to $187.00 in a research report issued on Monday, Benzinga reports ...
AbbVie (NYSE:ABBV) Price Target Cut to $180.00 by Analysts at BMO Capital Markets
ETF DAILY NEWS· 6 days agoAbbVie (NYSE:ABBV – Free Report) had its price objective cut by BMO Capital Markets from $195.00 to $180.00 in a report published on Monday morning, Benzinga reports. A number ...
